Many innovative drug designs fail because they are difficult to manufacture. LabGenius's ML platform avoids this by simultaneously optimizing for both biological function (e.g., potency) and "developability." This allows them to explore unconventional molecular designs without hitting a production wall later.
To overcome on-target, off-tumor toxicity, LabGenius designs antibodies that act like biological computers. These molecules "sample" the density of target receptors on a cell's surface and are engineered to activate and kill only when a specific threshold is met, distinguishing high-expression cancer cells from low-expression healthy cells.
The relationship between a multi-specific antibody's design and its function is often non-intuitive. LabGenius's ML platform excels by exploring this complex "fitness landscape" without human bias, identifying high-performing molecules that a rational designer would deem too unconventional or "crazy."
While its internal pipeline targets oncology, LabGenius partners with companies like Sanofi to apply its ML-driven discovery platform to other therapeutic areas, such as inflammation. This strategy validates the platform's broad applicability while securing non-dilutive funding to advance its own assets towards the clinic.